Nanfang Hospital, Southern Medical University
南方医科大学南方医院
Nanfang Hospital, Southern Medical University (南方医科大学南方医院) is a major hospital in China that appears in elsewhere's corpus primarily as a clinical collaborator in microbiome drug development. It partnered with biotech firm Xunknown (未知君) on a gut microbiota capsule program for acute graft-versus-host disease (aGvHD), with an IND application filed to the U.S. FDA in October 2020 . The hospital was also cited alongside Peking University Cancer Hospital and Peking Union Medical College Hospital as one of several prominent Chinese medical institutions where Xunknown ran clinical collaborations for its first-in-class microbiome drug pipeline as of late 2021 . elsewheres corpus does not contain further institutional detail on the hospital itself.
AI-generated — may contain errors, please verify.
Coverage
Unknown Closes Nearly $100 Million in Series B Funding, Launches AI×BT Strategy
Focused on gut microbiome AI-driven drug discovery, with self-developed drug candidates already in registrational clinical trials.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
5Y News｜Unknown Closes Tens of Millions of Dollars in Series B+ Funding to Advance Microbiome Drug Clinical Trials
Leading domestic microbiome therapeutics company Unknown has recently completed a tens-of-millions-of-dollars Series B+ funding round, with continued backing from 5Y Capital.
